Date:

C#

October 20, 1998

Asst. Commissioner of Patents Washington, D.C. 20231

80

June 6, 1995

Sir:

Inventor(s):

Appin. No.:

Filed:

Title:

REPLY/AMENDMENT/LETTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

"Small Entity" statement(s) filed						•	
previously herewith (No.)	Claims remaining after amendment	Highest number previously paid for		Present Extra	Large/Small Entity	Additional Fee	Fee Code
2. Total Effective Claims	20	**minus	20	0	x \$22/\$11 =	+ 0	103/203
3. Independent Claims	4	***minus	4	0	x \$82/\$41 =	+ 0	102/202
4. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time (leave <u>blank</u> if this is a <u>reissue</u> application)						+ 0	104/204
5. Original due Date: OCTOBER	R 20, 1998			40		47	
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) (2 mos) (3 mos)		\$110/\$55 = \$400/\$200 = \$950/\$475 =	+0		115/215 116/216 117/217
7. Enter any previous extension fee paid since above original due date and subtract -							
8. Extension Fee Attached						+ 0	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee						+ 0	148/248
10. If IDS attached requires Official Fee,					+ 0	126 122	
11. After-Final Request Fee per rules 129(a) and 17(r)						+0	146/246
12. No. of additional inventions for examination per Rule 129(b) x \$790/395 ea =						+ 0	149/249
13. Petition fee for						+	
14. TOTAL FEE ENCLOSED =						\$0	

- 15. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".
- 16. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.
- 17. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If	
so, file Notice of Appeals separate	l۷.

Pillsbury Madison & Sutro LLP Intellectual Property Group

1100 New York Avenue, N.W. By Atty: Ann S. Hobbs, Ph.D Ninth Floor East Tower

Washington, D.C. 20005-3918

Tel: (202) 861-3000 Atty/Sec: ASH/maf

Sig:

Reg. No. 36,830 Fax: (202) 822-0944

Tel: (202) 861-3063

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION

ENGEL et al

Appln. No. 08/468,145

Filed: June 6, 1995

Title: OLIGOPEPTIDE LYOPHILISATE, THEIR PREPARATION AND USE

Group Art Unit: 1811

Examiner: N. Minnifield

October 20, 1998

RESPONSE

Hon. Commissioner of Patents and Trademarks Washington, D C. 20231

Sir:

In response to the Office Action issued July 20, 1998, please consider the following remarks.

REMARKS

Claims 12-23 are under examination. Reconsideration is requested.

Claims 12-23 were rejected under 35 USC § 103 as being obvious over Callahan et al., Finkenaur, Reissman et al. and Moore, taken with Sauerbier et al. This rejection is traversed for the following reasons.

It is the Examiner's position that a skilled artisan would have been motivated to combine the cited references to realize a method of production of a sterile cetrorelix lyophilisate by dissolution in acetic acid, sterile filtration and subsequent lyophilization.

OX to

#17 1921/98 (NE)